Table of Contents

    Topic review

    MT-ND5 Gene

    Subjects: Genetics
    View times: 5
    Submitted by: Lily Guo
    (This entry belongs to Entry Collection "MedlinePlus ")

    Definition

    mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5

    1. Introduction

    The MT-ND5 gene provides instructions for making a protein called NADH dehydrogenase 5. This protein is part of a large enzyme complex known as complex I, which is active in mitochondria. Mitochondria are structures within cells that convert the energy from food into a form that cells can use. These cellular structures produce energy through a process called oxidative phosphorylation, which uses oxygen and simple sugars to create adenosine triphosphate (ATP), the cell's main energy source.

    Complex I is one of several enzyme complexes necessary for oxidative phosphorylation. Within mitochondria, these complexes are embedded in a tightly folded, specialized membrane called the inner mitochondrial membrane. During oxidative phosphorylation, mitochondrial enzyme complexes carry out chemical reactions that drive the production of ATP. Specifically, they create an unequal electrical charge on either side of the inner mitochondrial membrane through a step-by-step transfer of negatively charged particles called electrons. This difference in electrical charge provides the energy for ATP production.

    Complex I is responsible for the first step in the electron transport process, the transfer of electrons from a molecule called NADH to another molecule called ubiquinone. Electrons are then passed from ubiquinone through several other enzyme complexes to provide energy for the generation of ATP.

    2. Health Conditions Related to Genetic Changes

    2.1. Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes

    Mutations in the MT-ND5 gene are responsible for a small percentage of all cases of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). These mutations alter single DNA building blocks (nucleotides) in the gene. A particular mutation has been identified in at least five people with the characteristic features of MELAS; this mutation replaces the nucleotide guanine with the nucleotide adenine at gene position 13513 (written as G13513A). Most of the MT-ND5 mutations that cause MELAS have been shown to reduce the activity of complex I, which disrupts energy production within mitochondria. Although these abnormalities have the greatest impact on tissues that require a lot of energy (such as the brain and muscles), researchers have not determined how changes in the MT-ND5 gene lead to the specific signs and symptoms of MELAS.

    Mutations in the MT-ND5 gene also have been identified in patients with the major features of MELAS in combination with other mitochondrial diseases. For example, researchers have found MT-ND5 mutations in several individuals with the signs of MELAS and some features of Leigh syndrome, a progressive brain disorder that typically appears in infancy or early childhood. In other cases, people with MELAS and a change in the MT-ND5 gene have developed sudden, progressive vision loss characteristic of an eye disease called Leber hereditary optic neuropathy. A few individuals have been reported with signs and symptoms of all three of these mitochondrial conditions—MELAS, Leigh syndrome, and Leber hereditary optic neuropathy.

    It is unclear why changes in the MT-ND5 gene can cause such a large variety of signs and symptoms. Even within a single family, affected individuals may have different health problems caused by the same genetic change.

    2.2. Other disorders

    Mutations in the MT-ND5 gene have been identified in at least 10 people with Leigh syndrome. Children with this condition may experience vomiting, seizures, delayed development, muscle weakness, and problems with movement. Heart disease, kidney problems, and difficulty breathing can also occur in people with this disorder. A few affected children with MT-ND5 mutations have had additional features that are not typical of Leigh syndrome, including slow growth before birth (intrauterine growth retardation) and distinctive facial features.

    The MT-ND5 mutations responsible for Leigh syndrome change single nucleotides in the gene. These genetic changes disrupt the activity of complex I, impairing the ability of mitochondria to produce energy. It is not known, however, how mutations in the MT-ND5 gene are related to the specific features of Leigh syndrome.

    3. Other Names for This Gene

    • mitochondrially encoded NADH dehydrogenase 5

    • MTND5

    • NADH dehydrogenase subunit 5

    • NADH-ubiquinone oxidoreductase chain 5

    • NADH-ubiquinone oxidoreductase, subunit ND5

    • NADH5

    • ND5

    • NU5M_HUMAN

    The entry is from https://medlineplus.gov/genetics/gene/mt-nd5

    References

    1. Chol M, Lebon S, Bénit P, Chretien D, de Lonlay P, Goldenberg A, Odent S,Hertz-Pannier L, Vincent-Delorme C, Cormier-Daire V, Rustin P, Rötig A, MunnichA. The mitochondrial DNA G13513A MELAS mutation in the NADH dehydrogenase 5 gene is a frequent cause of Leigh-like syndrome with isolated complex I deficiency. J Med Genet. 2003 Mar;40(3):188-91.
    2. Corona P, Antozzi C, Carrara F, D'Incerti L, Lamantea E, Tiranti V, Zeviani M.A novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients. AnnNeurol. 2001 Jan;49(1):106-10.
    3. Crimi M, Galbiati S, Moroni I, Bordoni A, Perini MP, Lamantea E, Sciacco M,Zeviani M, Biunno I, Moggio M, Scarlato G, Comi GP. A missense mutation in themitochondrial ND5 gene associated with a Leigh-MELAS overlap syndrome. Neurology.2003 Jun 10;60(11):1857-61.
    4. Kirby DM, Boneh A, Chow CW, Ohtake A, Ryan MT, Thyagarajan D, Thorburn DR. Lowmutant load of mitochondrial DNA G13513A mutation can cause Leigh's disease. Ann Neurol. 2003 Oct;54(4):473-8.
    5. Liolitsa D, Rahman S, Benton S, Carr LJ, Hanna MG. Is the mitochondrialcomplex I ND5 gene a hot-spot for MELAS causing mutations? Ann Neurol. 2003Jan;53(1):128-32.
    6. Mitchell AL, Elson JL, Howell N, Taylor RW, Turnbull DM. Sequence variation inmitochondrial complex I genes: mutation or polymorphism? J Med Genet. 2006Feb;43(2):175-9.
    7. Pulkes T, Eunson L, Patterson V, Siddiqui A, Wood NW, Nelson IP, Morgan-HughesJA, Hanna MG. The mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS. Ann Neurol.1999 Dec;46(6):916-9. Erratum in: Ann Neurol 2000 Jun;47(6):841.
    8. Santorelli FM, Tanji K, Kulikova R, Shanske S, Vilarinho L, Hays AP, DiMauroS. Identification of a novel mutation in the mtDNA ND5 gene associated withMELAS. Biochem Biophys Res Commun. 1997 Sep 18;238(2):326-8.
    9. Sudo A, Honzawa S, Nonaka I, Goto YI. Leigh syndrome caused by mitochondrialDNA G13513A mutation: frequency and clinical features in Japan. J Hum Genet.2004;49(2):92-96. doi: 10.1007/s10038-003-0116-1.
    10. Valentino ML, Barboni P, Rengo C, Achilli A, Torroni A, Lodi R, Tonon C,Barbiroli B, Fortuna F, Montagna P, Baruzzi A, Carelli V. The 13042G --> A/ND5mutation in mtDNA is pathogenic and can be associated also with a prevalentocular phenotype. J Med Genet. 2006 Jul;43(7):e38.
    More

    Keywords